PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Trial shows treatment-resistant advanced non-small cell lung cancer responds to rociletinib

2014-11-19
(Press-News.org) Barcelona, Spain: A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial. The research will be presented today (Friday) at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Approximately 10-15% of Caucasian and 30-35% of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib. However, these patients will eventually develop resistance to EGFR TKI therapy and a further EGFR mutation called T790M accounts for 60% of this acquired resistance.

Professor Jean-Charles Soria, Chairman of the Drug Development Department at Gustave Roussy Cancer campus, France, will tell the Symposium: "Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get worse. Rociletinib (CO-1686) is a new and potent oral EGFR inhibitor designed to selectively target both the initial activating EGFR mutations as well as the T790M resistance mutation. This compound spares normal (wild-type) EGFR and this means that it causes far fewer toxic side-effects than other EGFR inhibitors. Therefore, it may benefit patients both as a first-line and second- or later-line treatment, by producing a durable clinical benefit and with a reduced toxicity profile compared to current EGFR inhibitor therapies. Current TKIs inhibit the normal EGFR as well as the mutant EGFR, causing acne-like skin rashes and paronychia - an inflammation of the folds of tissue around finger and toe nails - both of which can be very troublesome for patients."

Patients with advanced NSCLC with the EGFR mutation, with or without the T790M resistance mutation, were enrolled in the phase I/II clinical trial in centres in Europe, Australia and the USA; enrolment of patients for the phase I part of the study began in March 2012, and for the phase II part in August 2013. The phase I portion of the study examined two formulations and multiple doses and schedules of rociletinib; 625mg twice a day continuously of hydrobromide (HBr) salt tablet form of rociletinib was identified as the pivotal dose, schedule and formulation for the phase II part of the study.

By October 2014, 179 patients had been treated at therapeutic doses (either 900mg twice a day of freebase formulation, or 500mg or more twice a day of HBr salt tablet). Preliminary results for all of these patients (those with and without the T790M and T790M resistance mutation) include an overall response rate of 46% and a disease control rate of 84%.

Prof Soria will present detailed data to the Symposium on 56 patients who had the T790M resistance mutation and received the pivotal dose and formulation (625mg twice a day) or the reduced dose of 500mg twice a day. The median number of prior therapies for these patients was three; all the patients had been treated previously with at least one other EGFR TKI therapy, and most patients receiving chemotherapy as well. Approximately 80% of these patients were treated immediately after their cancer progressed during treatment with a TKI. The study is ongoing, accruing patients rapidly, and CT scan data are available on 27 of these patients, of whom 18 had a confirmed response to the treatment, giving an overall response rate of 67% and a median progression-free survival of 10.4 months.

Among an additional 11 evaluable patients who did not have the T790M mutation, four had a confirmed response to the treatment (overall response rate of 36%) and this group of patients had a median progression-free survival of 7.5 months. Prof Soria will say: "Re-sensitisation to TKI cannot account for the majority of these responses, since most patients had come off TKI as their immediate prior therapy."

Adverse side-effects of rociletinib were manageable and included asymptomatic hyperglycaemia (high blood sugar levels), nausea and diarrhoea, and these were mostly mild or moderate (grade 1 or 2). Only two patients had any form of rash, which was grade 1 and transient. The most common, more severe adverse event (grade 3) was hyperglycaemia, which was observed in 14% of patients. Hyperglycaemia can usually be managed with a commonly-prescribed oral drug.

Prof Soria will say: "Eventually, almost all lung cancer patients with EGFR mutations will develop resistance to currently available therapies, including TKI, leaving doctors and patients without effective options to treat this deadly disease. The data from the rociletinib clinical trials suggest that we may be able to successfully target and overcome resistance to EGFR inhibitors and bring new, targeted treatments to patients who need them the most."

The responses seen in the patients who had acquired resistance to earlier TKI treatment but without evidence of T790M mutation was unexpected. Possible explanations include: the presence of large regions of tumour that do have the T790M mutation, but were missed by the biopsy needle (tumour heterogeneity); the test is not sensitive enough to detect low levels of the T790M mutation, resulting in a false negative; rociletinib inhibits an alternative pathway (a "bypass track"), other than EGFR, which drives acquired resistance to EGFR TKI. "Indeed, we now know a metabolite of rociletinib inhibits the IGF1-R pathway, which we believe may account for some of the activity observed in T790M-negative patients," Prof Soria will say.

INFORMATION:

Professor Josep Tabernero, a member of the scientific committee for the EORTC-NCI-AACR Symposium and head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: "Lung cancer is an extremely difficult disease to treat successfully, with only about one in ten patients living for five years or longer. Drug resistance is one of the main problems encountered when trying to treat it; therefore, a therapy that can overcome this resistance in the proportion of patients with non-small cell lung cancer with EGFR mutations is an important step forward. Rociletinib precisely targets the EGFR mutant population with the specific T790M mutation, leaving normal EGFR unaffected, and this means that it offers patients the possibility of a longer life with fewer of the adverse side-effects encountered with other drugs."

EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research]. TKI (tyrosine kinase inhibitors) inhibit tyrosine kinases, which are enzymes that trigger the cancer-causing activity of the epidermal growth factor receptor (EGFR).



ELSE PRESS RELEASES FROM THIS DATE:

High heels may enhance a man's instinct to be helpful

2014-11-19
If it's help a woman needs, maybe she should wear high heels. That's the message from Nicolas Guéguen of the Université de Bretagne-Sud in France, after he observed how helpful men are towards women in high heels versus those wearing flat, sensible shoes. The study, published in Springer's journal Archives of Sexual Behavior, is the first ever to investigate how the height of a woman's shoe heel influences how men behave towards her. Research across various cultures has shown at length how important physical features, such as body size and the style and color ...

Climate change in drylands

2014-11-19
Approximately 40 percent of the earth's surface is covered by drylands in which average annual precipitation is lower than evaporation. The changes projected to unfold in these areas in the course of climate change are alarming. Greater variations in annual and seasonal precipitation will lead to more frequent droughts and, presumably, longer drought periods. This means that drylands are among those areas most severely affected by climate change. Research has thus far not adequately addressed the question of how strongly annual plant growth in pasture landscapes - hence ...

Fountain of youth underlies Antarctic Mountains

Fountain of youth underlies Antarctic Mountains
2014-11-19
Time ravages mountains, as it does people. Sharp features soften, and bodies grow shorter and rounder. But under the right conditions, some mountains refuse to age. In a new study, scientists explain why the ice-covered Gamburtsev Mountains in the middle of Antarctica looks as young as they do. The Gamburtsevs were discovered in the 1950s, but remained unexplored until scientists flew ice-penetrating instruments over the mountains 60 years later. As this ancient hidden landscape came into focus, scientists were stunned to see the saw-toothed and towering crags of much ...

Cochrane Review of reminder systems to improve TB diagnoses and care

2014-11-19
Researchers from China, the Philippines and LSTM have today published a new systematic review of reminder systems to improve patient adherence to tuberculosis (TB) treatment. Reminder systems include prompts in advance of a forthcoming appointment to help ensure the patients attend, and also actions when people miss an appointment, such as phoning them or arranging a home visit. This review is the latest in a suite of reviews produced by authors from the Cochrane Infectious Diseases Group, hosted at LSTM, evaluating interventions to improve adherence to TB treatment. Effective ...

Lumosity study examines lifestyle effects on cognitive training at Neuroscience 2014

2014-11-19
Washington, D.C. - November 19, 2014 - Lumosity is presenting new research today at the 2014 Society for Neuroscience conference on how lifestyle factors such as sleep, mood and time of day impact cognitive gameplay performance. The study, titled "Estimating sleep, mood and time of day effects in a large database of human cognitive performance," analyzed over 60 million data points from 61,407 participants and found that memory, speed, and flexibility tasks peaked in the morning, while crystallized knowledge tasks such as arithmetic and verbal fluency peaked in the afternoon. ...

Seed dormancy, a property that prevents germination, already existed 360 million years ago

Seed dormancy, a property that prevents germination, already existed 360 million years ago
2014-11-19
An international team of scientists, coordinated by a researcher from the U. of Granada, has found that seed dormancy (a property that prevents germination under non-favourable conditions) was a feature already present in the first seeds, 360 million years ago. Seed dormancy is a phenomenon that has intrigued naturalists for decades, since it conditions the dynamics of natural vegetation and agricultural cycles. There are several types of dormancy, and some of them are modulated by environmental conditions in more subtle ways than others. In an article published in the ...

Spooky alignment of quasars across billions of light-years

Spooky alignment of quasars across billions of light-years
2014-11-19
Quasars are galaxies with very active supermassive black holes at their centres. These black holes are surrounded by spinning discs of extremely hot material that is often spewed out in long jets along their axes of rotation. Quasars can shine more brightly than all the stars in the rest of their host galaxies put together. A team led by Damien Hutsemékers from the University of Liège in Belgium used the FORS instrument on the VLT to study 93 quasars that were known to form huge groupings spread over billions of light-years, seen at a time when the Universe ...

Many older brains have plasticity, but in a different place

2014-11-19
PROVIDENCE, R.I. [Brown University] -- A widely presumed problem of aging is that the brain becomes less flexible -- less plastic -- and that learning may therefore become more difficult. A new study led by Brown University researchers contradicts that notion with a finding that plasticity did occur in seniors who learned a task well, but it occurred in a different part of the brain than in younger people. When many older subjects learned a new visual task, the researchers found, they unexpectedly showed a significantly associated change in the white matter of the brain. ...

Mind the gap -- how new insight into cells could lead to better drugs

2014-11-19
Professor Dan Davis and his team at the Manchester Collaborative Centre for Inflammation Research, working in collaboration with global healthcare company GSK, investigated how different types of immune cells communicate with each other - and how they kill cancerous or infected cells. Their research has been published in Nature Communications. Professor Davis says: "We studied the immune system and then stumbled across something that may explain why some drugs don't work as well as hoped. We found that immune cells secrete molecules to other cells across a very small ...

When it comes to teen alcohol use, close friends have more influence than peers

When it comes to teen alcohol use, close friends have more influence than peers
2014-11-19
A recent study by an Indiana University researcher has found that adolescents' alcohol use is influenced by their close friends' use, regardless of how much alcohol they think their general peers consume. Jonathon Beckmeyer, assistant professor in the Department of Applied Health Science at the IU School of Public Health-Bloomington and author of the study, said his research generally focuses on the onset of teen alcohol use and how their social relationships shape those experiences. "We've known for a long time that friends and peers have an influence on individual ...

LAST 30 PRESS RELEASES:

Being physically active, even just a couple of days a week, may be key to better health

High-fat diet promote breast cancer metastasis in animal models

A router for photons

Nurses and AI collaborate to save lives, reduce hospital stays

Multi-resistance in bacteria predicted by AI model

Tinker Tots: A citizen science project to explore ethical dilemmas in embryo selection

Sensing sickness

Cost to build multifamily housing in California more than twice as high as in Texas

Program takes aim at drinking, unsafe sex, and sexual assault on college campuses

Inability to pay for healthcare reaches record high in U.S.

Science ‘storytelling’ urgently needed amid climate and biodiversity crisis

KAIST Develops Retinal Therapy to Restore Lost Vision​

Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response

Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid

Low LDL cholesterol levels linked to reduced risk of dementia

Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients

Almost one in ten people surveyed report having been harmed by the NHS in the last three years

Enhancing light control with complex frequency excitations

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

New insight into factors associated with a common disease among dogs and humans

Illuminating single atoms for sustainable propylene production

New study finds Rocky Mountain snow contamination

Study examines lactation in critically ill patients

UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award

Doubling down on metasurfaces

New Cedars-Sinai study shows how specialized diet can improve gut disorders

Making moves and hitting the breaks: Owl journeys surprise researchers in western Montana

PKU Scientists simulate the origin and evolution of the North Atlantic Oscillation

ICRAFT breakthrough: Unlocking A20’s dual role in cancer immunotherapy

How VR technology is changing the game for Alzheimer’s disease

[Press-News.org] Trial shows treatment-resistant advanced non-small cell lung cancer responds to rociletinib